DEF: Whitehawk Therapeutics Sets 2026 Annual Meeting Date

Whitehawk Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026, to elect directors, approve executive compensation, and ratify auditor appointment.

Summary

• Whitehawk Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on June 11, 2026, at 1:00 p.m. Eastern Time.
• The meeting agenda includes the election of three Class III directors, an advisory vote on executive compensation for the 2025 fiscal year, and the ratification of BDO USA, P.C. as the independent registered accounting firm for the fiscal year ending December 31, 2026.
• Stockholders of record as of April 17, 2026, are eligible to vote.
• Proxy materials will be available online on or about April 28, 2026.
• The company previously completed the divestiture of its FYARRO business and changed its name from Aadi Bioscience, Inc. to Whitehawk Therapeutics, Inc. on March 25, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, primarily due to its routine nature as a proxy statement for an annual meeting. While it details important governance matters and a past capital raise, it lacks new operational or financial performance updates that would significantly sway sentiment.

Positives

• The company is holding its annual meeting to ensure shareholder engagement and governance.
• The appointment of BDO USA, P.C. as auditor is being ratified, indicating a continuation of established financial oversight.
• The company has a clear process for director nominations and stockholder proposals.
• A majority of the board members are considered independent, meeting Nasdaq listing standards.

Negatives

• Two Section 16(a) filings were late in fiscal year 2025: one for Neil Desai regarding an option award, and three for David Lennon, Scott Giacobello, and Bryan Ball concerning vesting of restricted stock units and subsequent sales.
• The company's stock price has experienced significant negative TSR in recent years, with a $100 investment in 2025 decreasing to $18.86 by year-end, and a substantial net loss reported for 2025.

Risks

• The company faces risks related to its financial condition, development activities, operations, strategic direction, and intellectual property, as detailed in its SEC filings.
• The divestiture of the FYARRO business means the company no longer operates in that segment, which could impact future revenue streams or strategic focus.
• The company's stock performance has been volatile, with a significant decline in Total Shareholder Return (TSR) over the past three years.

Future Outlook

The filing does not contain specific forward-looking financial guidance. It outlines the agenda for the upcoming annual meeting, which includes electing directors, approving executive compensation, and ratifying the appointment of the independent auditor.

Management Comments

• "Your investment and continuing interest in the Company are very much appreciated."
• "We believe that separating these positions allows our Chief Executive Officer to focus on our day-to-day business, while allowing a chairman of the board to lead the Board in its fundamental role of providing advice to and independent oversight of management."
• "We believe our approach to goal setting, setting of targets with payouts at multiple levels of performance, and evaluation of performance results assist in mitigating excessive or inappropriate risk-taking."

Industry Context

StockSavvy.ai notes that this filing is typical for a publicly traded biotechnology company preparing for its annual shareholder meeting. The focus on director elections, executive compensation, and auditor ratification are standard governance procedures. The company's recent divestiture of its FYARRO business and name change suggest a strategic pivot or restructuring, which is common in the dynamic biotech sector.

Comparison to Industry Standards

• The company's board composition includes a majority of independent directors, aligning with Nasdaq listing requirements and best practices for corporate governance in the biotechnology sector.
• The executive compensation structure, including base salary, bonuses, and equity awards, is typical for the industry, with a focus on aligning executive interests with stockholder value.
• The company's engagement of BDO USA, P.C. as its independent auditor is consistent with industry practice, where reputable accounting firms are retained for financial oversight.

Corporate Governance

Related Party Transactions

• Participation in the PIPE Financing by directors (Casey Castelein, M.D., Anupam Dalal, M.D., Behzad Aghazadeh, Ph.D., Baiteng Zhao, Ph.D.) and executive officer (Bryan Ball).
• Entities affiliated with directors Dr. Aghazadeh (Avoro), Dr. Dalal (Acuta), Dr. Castelein (KVP Capital), and Dr. Zhao (WZCUBE LLC) were investors in the PIPE Financing.
• Support agreements were entered into with directors, executive officers, and affiliates, requiring them to vote in favor of the Divestiture and PIPE Financing.

Stakeholder Impact

• Shareholders: The election of directors and advisory vote on executive compensation directly impact shareholder representation and executive accountability. The PIPE financing may dilute existing shareholders but provides capital.
• Employees: Executive compensation and retention bonuses are detailed, indicating focus on retaining key personnel. The company offers a 401(k) plan.
• Management: Employment agreements and severance packages are outlined, providing security for named executive officers.
• Auditors: The ratification of BDO USA, P.C. as auditor ensures continued financial auditing services.

Next Steps

• Elect three Class III directors to serve until the 2029 annual meeting.
• Approve, on an advisory basis, the compensation of named executive officers for the 2025 fiscal year.
• Ratify the appointment of BDO USA, P.C. as the independent registered accounting firm for the fiscal year ending December 31, 2026.
• Stockholders are urged to vote their proxies via Internet, telephone, or mail.
• The company will report final voting results by filing a Form 8-K within four business days after the Annual Meeting.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new operational or financial performance data that would warrant a buy or sell recommendation. It outlines governance procedures, director nominations, and executive compensation, which are standard for public companies. The company's recent divestiture and past capital raise are noted, but without current performance metrics, a 'hold' recommendation is appropriate, suggesting investors monitor future operational updates.

Keywords

Whitehawk Therapeutics, DEF 14A, Proxy Statement, Annual Meeting, Stockholders, Director Election, Executive Compensation, Auditor Ratification, Corporate Governance, SEC Filing